



31856-A-PCT-USA-070050.1238

PATENT

TECH CENTER 1600/2900

RECEIVED
DEC 20 2002

#1644 PTH

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: The Trustees of Columbia University in the City of New York

Serial No.: 09/509,734 Examiner: Saunders, D.

Filed : June 14, 2000 Group Art Unit: 1644

For : METHOD OF PREDICTING TRANSPLANT REJECTION

INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on:

December 11, 2002

Date of Deposit

Carmella L. Stephens

Attorney Name

41,328

PTO Reg. No.

Carmella L. Stephens
SignatureDecember 11, 2002

Date of Signature

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §1.56, Applicants respectfully request that the following references relating to the above-referenced application be made of record in the U.S. Patent and Trademark Office:

1. Hosenpud J.F., Novick R.J., Bennett L.E., Keck B.M., Fiol B., Daily P.O. The Registry of the International Society of Heart and Lung Transplantation 1996; 15:655.
2. Kormos, R., Arimtage, J., Wolyn, T. et al. Graft atherosclerosis: effects of cellular rejection and human lymphocyte antigen. The Journal of Heart and Lung Transplantation 1992; 11(3): S104-110.
3. Kerman, R.H., Kimball, P., Scheinen, S. et al. The relationship among donor-recipient HLA mismatches, rejection, and death

12/18/2002 DEMMANU1 00000094 09509734

01 FC:1806

180.00 OP

PATENT

from coronary artery disease in cardiac transplant recipients.
Transplantation 1994; 57(6); 884-8.

4. Smith, J.D., Rose, M.L., Pomerance, A., Burke, M., Yacoub, M.H. Reduction of cellular rejection and increase in longer-term survival after heart transplantation after HLA-DR matching. Lancet 1995; 346:1318-22.
5. Costanzo-Nordin, M.R. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. The Journal of Heart and Lung Transplantation 1992; 11:S90-103.
6. Suciu-Foca N., Reed E., Marboe C., Xi Y.P., Kai S.Y., Ho E., Rose E.A., Reemstma K., King, D.W. Role of anti-HLA antibodies in heart transplantation. Transplantation 1991; 51:716-724.
7. Hess M., Hastillo A., Mohanakamar T., Crowley J.J., Vetrovac G., Szentpetery, S., Wolfgang, T.C., Lower R.R.. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation 1983; 68:94-101.
8. Rose, E.A., Pepino P., Barr M., Smith C., Ratner A., Ho E., Berger C. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. The Journal of Heart and Lung Transplantation 1992; S120-123.
9. DeMattos, A.M. Head M.A., Everett, J., et al. HLA-DR mismatching correlates with early cardiac allograft rejection, incidence, and graft survival when high-confidence-level serological DR typing is used. Transplantation 1994; 57(4);626-630.
10. Kriklin, J.K., Bourge, R.C., BBarr, M.L., et al. Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. The cardiac transplant research database group. The Journal of Heart and Lung Transplantation. 1995; 13(4); 583-95.
11. Keogh, A., Kaan, A., Doran, T., et al. HLA mismatching and outcome in heart, heart-lung and single lung transplantation. The Journal of Heart and Lung Transplantation. 1995; 14(3);444-51.

12. Rizeq, M., Masek, M.A., and Billingham, M.E. Acute rejection: significance of elapsed time after transplantation. *The Journal of Heart and Lung Transplantation*. 1994; 13(5); 862-868.
13. Winters, G.L., Loh, E., Schoen, F.J., Natural history of focal moderate cardiac allograft rejection: is treatment warranted. *Circulation*. 1995; 91:1975-1980.
14. White J.A., Guirandon C., Pfluglelder P.W., Kostuk W.J. Routine surveillance myocardial biopsies are unnecessary beyond one year after heart transplantation. *The Journal of Heart and Lung Transplantation* 1995; 14:1052.
15. Smith, J.D., Danskin, A.J., Taylor, R.M., Rose, M.L., and Yacoub, M.H. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. *Transplant Immunology* 1993; 1:60-65.
16. Rose, E.A., Smith, C.R., Petrossian, G.A., Barr, M.L., Reemtsma, K. Humoral immune responses after cardiac transplantation: correlation with fatal rejection and graft atherosclerosis. *Surgery* 1989; 106:203-208.
17. Kemkes, B.M., Schultz, A., Engelhardt, M., Brandl, U., and Breuer, M. Noninvasive methods of rejection diagnosis after heart transplantation. *The Journal of Heart and Lung Transplantation* 1992; 11:S221-S231.
18. Hall T., Baumgartner W., Borkin A., et al. Diagnosis of acute cardiac rejection with antimyosin antibody monoclonal antibody, phosphorus nuclear magnetic imaging, two dimensional echocardiography and endocardial biopsy. *The Journal of Heart Transplantation* 1986; 6:419-24.
19. Wisenberg G., Pflugfelder J.V., Kostuk, W.J., McKenzie F.N., Prato F.S. Diagnostic applicability of magnetic resonance imaging in assessing human cardiac allograft rejection. *American Journal of Cardiology* 1987; 53:130.
20. George, J.F., Kirklin, J.K., Shroyer, T.W., et al. Utility of a posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients. *The Journal of Heart and Lung Transplantation* 1995; 14:856-864.

21. Smith, J.D., Danskine, A.J., Rose, M.L., and Yacoub, M.H. Specificity of lymphocytotoxic antibodies formed after cardiac transplantation and correlation with rejection episodes. *Transplantation* 1992; 53:1358-62.
22. Zavazava, N., Botcher, H., and Ruchholtz, W.M., Soluble MHC Class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients. *Tissue Antigens* 1993; 42:20-26.
23. Fischer, P.E., Suciu-Foca, N., Ho, E., Tugulea, S., Rose E.A., Michler, R.E., Mancini, D. Additive value of immunologic monitoring to histologic grading of heart allograft biopsy specimens: implications for therapy. *Journal of Heart and Lung Transplantation* 1995; 14:1156-1161.
24. Liu, Z., Sun, Y.K., Xi, Y.P., Maffei, A., Harris, P.E., Suciu-Foca, N. Contribution of direct and indirect recognition pathway to T cell alloreactivity. *Journal of Experimental Medicine* 1993; 177:1643-1650.
25. Liu, Z., Colovai, A.I., Tugulea, S., Reed, E.F., Fisher, P.E., Mancini, D., Rose, E.A., Cortesini, R., Michler, R.E., Suciu-Foca, N., Indirect Recognition of donor HLA-DR peptides in organ allograft rejection. *Journal of Clinical Investigation* 1996; 98:1150-1157.
26. Tugulea, S., Ciubotariu, R., Colovai, A.I., Liu, Z., Itescu, S., Schulman, L., Fisher, P.E., Hardy, M.A., Rose, E.A., Michler, R.E., Cortesini, R., Suciu-Foca, N. New strategies for early diagnosis of heart allograft rejection. *Transplantation* 1997; 64:842-847.
27. Ciubotariu, R., Colovai, A.I., Ho, E., Itescu, S., Ravalli, S., Hardy, M.A., Cortesini, R., Rose, E.A., Suciu-Foca, N. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. *Journal of Clinical Investigation* 1998; 101:398-405.
28. Markus, P.M., Salvaggi, G., Cai, X., Fung, J.J., Starzl, T.E. Induction of donor-specific transplantation tolerance of skin and cardiac allografts using miced chimerism in (A+B →A) in rats. *Cell Transplantation* 1993; 2:345-353.
29. Zeevi, A., Pavlick, M., Lombardozzi, S., Banas, R., Pappo, O., Rao, A.S., Fontes, P., Demetris, J., Shapiro, R., Dodson, E., et al. Immune status of recipients following bone marrow-

augmented solid organ transplantation. *Transplantation* 1995; 59:616:620.

30. Creemers, P. Du Toit, E., Cassidy, M.J., Kahn, D. Sequential mixed lymphocyte culture after kidney transplantation: induction of tolerance or sensitization. *Nephron* 1997; 75:166-170.
31. Billingham, M.E. Dilemma of variety of histopathologic grading systems for acute cardiac allograft rejection by endomyocardial biopsy. *Journal of Heart Transplantation* 1990; 9:272-276.
32. Kaplan, E.L., and Meier, P. Nonparametric estimation from incomplete observations. *Journal of the American Statistic Association* 1958; 53: 457-481.
33. Liang, K.Y., and Zenger, S.L. Longitudinal data analysis using generalized linear models. *Biometrika* 1986; 73:13-22.
34. Krieger, N.R., Yin, D.P., and Fathman, C.G. CD4+ but not CD8+ cells are essential for allorejection. *Journal of Experimental Medicine* 1996; '84:2013-2018.
35. Starzl, T.E., Demetris, A.J., Rao, A.S., Thompson, A.M., Trucco, M., Murase, N. Migratory nonparenchymal cells after organ allograft transplantation: with particular reference to chimerism and the liver. *Progress in Liver Diseases* 1994; 12:191-213.
36. Schlitt, H.J., Hundrieser, J., Hisanaga, M., Uthoff, K., Karck, M., Wahlers, T., Wonigeit, K., Pichlmayr, R. Patterns of donor type microchimerism after heart transplantation. *Lancet* 1994; 343:1469-1471.
37. Hisanaga, M., Hundrieser, J., Boker, K., Uthoff, K., Raddatz, G., Wahlers, T., Wonigeit, K., Pichlmayr, R., Schlitt, H.J. Development, stability, and clinical correlations of allogeneic microchimerism after solid organ transplantation. *Transplantation* 1996; 61:40-45.
38. Vanderlugt, C.J. and Miller, S.D., Epitope spreading. *Current Opinion in Immunology* 1996; 8:831-836.
39. Mamula, M.J. and Janeway, C.A. Jr. Do B cells drive the diversification of immune responses? *Immunology Today* 1993; 14:151-154.

PATENT

40. Reed, E.F., Hong, B., Ho, E., Harris, P.E., Weinberger, J., Suciu-Foca, N. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant associated coronary artery disease. *Transplantation* 1996; (61)566-72.
41. Itescu, S., Weinberg, A., Burke, E.M., Tung, T., Oz, M., Reed, E., Suciu-Foca, N., Rose, E.A., Michler, P.E. Influence of pre-formed IgG anti-HLA antibodies on development of cellular rejection in highly sensitized cardiac allograft recipients. *The Journal of Heart and Lung Transplantation* 1997; 16(1): 78.
42. Lavee, J., Kormos, R.L., Duquesnoy, R.J., Zerbe, T.R., Armitage, J.M., Vaneck, B.S., Hardesty, R.L., and Griffith, B.P. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. *Journal of Heart and Lung Transplantation* 1991; 6:921-930.
43. Loh, E., Bergin, J.D., Couper, G.S., Mudge, G.H. Role of panel-reactive antibody cross-reactivity in predicting survival after orthotopic heart transplantation. *Journal of Heart and Lung Transplantation* 1994; 13:194-201.
44. Valentine, H.A., Yeoh, T.K., Gibbons, R., McCarthy, P., Stinson, E.B., Billingham, M.E., Popp, R.L. Sensitivity and specificity of diastolic indexes for rejection surveillance: temporal correlation with endomyocardial biopsy. *Journal of Heart and Lung Transplantation* 1991; 10:757-765.

The referenced citation is listed in the accompanying PTO Form 1449 and a copy of the references is provided. Identification of the above-listed reference is not to be construed as an admission of the Applicants or the attorneys of the Applicants that such reference is available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the above-mentioned application.

PATENT

This Information Disclosure Statement is being filed under §1.97(c), with fee, prior to either a final action or a notice of allowance. A check for the fee required by §1.17(p) and a duplicate copy of this Statement is enclosed.

The Commissioner is hereby authorized to charge payment of any additional fee to Deposit Account No. 02-4377.

Respectfully submitted,

Dated: December 11, 2002

Carmella L. Stephens
Carmella L. Stephens
Patent Office Reg. No. 41,328

BAKER BOTTS L.L.P.
30 Rockefeller Plaza
New York, New York 10112-4498

Attorney for Applicant
(212) 408-2539

O/I/P E JC81
DEC 16 2002
U.S. PATENT & TRADEMARK OFFICE

RECEIVED

DEC 20 2002

BAKER BOTTS LLP

TECH CENTER 1600/2900

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT	(\\$) 180
-------------------------	-----------

Complete if Known

Application Number	09/509,734
Filing Date	06/14/2000
First Named Inventor	Itescu, S.
Examiner Name	1644
Group Art Unit	David A. Saunders
Attorney Docket No.	A31856-PCT-USA

METHOD OF PAYMENT

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number **02-4377**

Deposit Account Name **Baker Botts LLP**

Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

Applicant claims small entity status. See 37 CFR 1.27

2. Payment Enclosed:

Check Credit card Money Order Other

FEE CALCULATION

1. **BASIC FILING FEE**

Large Entity Small Entity

Fee (\$)	Fee (\$)	Fee Description	Fee Paid
740	370	Utility filing fee	
330	165	Design filing fee	
510	255	Plant filing fee	
740	370	Reissue filing fee	
160	80	Provisional filing fee	

SUBTOTAL (1) (\\$) 0

2. **EXTRA CLAIM FEES**

Total Claims	Extra Claims	Fee from below	Fee Paid
<input type="text"/>	20 ** = <input type="text"/>	<input type="text"/> X <input type="text"/> = <input type="text"/> 0	
<input type="text"/>	3 ** = <input type="text"/>	<input type="text"/> X <input type="text"/> = <input type="text"/> 0	
			<input type="text"/> = <input type="text"/>

Large Entity Small Entity

Fee (\$)	Fee (\$)	Fee Description
18	9	Claims in excess of 20
84	42	Independent claims in excess of 3
280	140	Multiple dependent claim, if not paid
84	42	** Reissue independent claims over original patent
18	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\\$) 0

*for number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. **ADDITIONAL FEES**

Large Entity	Small Entity	Fee Description	Fee Paid
130	65	Surcharge - late filing fee or oath	
50	25	Surcharge - late provisional filing fee or cover sheet	
130	130	Non-English specification	
2,520	2,520	For filing a request for ex parte reexamination	
920*	920*	Requesting publication of SIR prior to Examiner action	
1,840*	1,840*	Requesting publication of SIR after Examiner action	
110	55	Extension for reply within first month	
400	200	Extension for reply within second month	
920	460	Extension for reply within third month	
1,440	720	Extension for reply within fourth month	
1,960	980	Extension for reply within fifth month	
320	160	Notice of Appeal	
320	160	Filing a brief in support of an appeal	
280	140	Request for oral hearing	
1,510	1,510	Petition to institute a public use proceeding	
110	55	Petition to revive - unavoidable	
1,280	640	Petition to revive - unintentional	
1,280	640	Utility issue fee (or reissue)	
460	230	Design issue fee	
620	310	Plant issue fee	
130	130	Petitions to the Commissioner	
50	50	Processing fee under 37 CFR 1.17(q)	
180	180	Submission of Information Disclosure Stmt	180
40	40	Recording each patent assignment per property (times number of properties)	
740	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
740	370	For each additional invention to be examined (37 CFR § 1.129(b))	
740	370	Request for Continued Examination (RCE)	
900	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\\$) 180

SUBMITTED BY		Complete (if applicable)	
Name (Print/Type)	Carmella L. Stephens	Registration No. (Attorney/Agent)	41,328
Signature	<i>Carmella L. Stephens</i>	Telephone	(212)408-2539

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.